Ginkgo Bioworks (NYSE:DNA) Posts Quarterly Earnings Results, Misses Expectations By $0.37 EPS

Ginkgo Bioworks (NYSE:DNA - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.45) by ($0.37), Zacks reports. The firm had revenue of $43.85 million during the quarter, compared to analyst estimates of $44.43 million. Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. Ginkgo Bioworks updated its FY 2025 guidance to EPS.

Ginkgo Bioworks Stock Down 5.2 %

DNA traded down $0.45 during trading on Friday, hitting $8.20. The stock had a trading volume of 2,260,857 shares, compared to its average volume of 1,830,178. The company has a market capitalization of $471.04 million, a price-to-earnings ratio of -0.63 and a beta of 1.16. The business has a 50-day moving average of $11.49. Ginkgo Bioworks has a twelve month low of $5.26 and a twelve month high of $64.40.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.